CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Celgene Corporation

86 Morris Avenue
Summit, NJ 07901
United States
908-673-9000
http://www.celgene.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees8,852

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark J. AllesChairman & CEO4.17MN/A1959
Mr. David V. ElkinsExec. VP & CFO2.09MN/A1969
Mr. Peter N. KelloggExec. VP & Chief Corp. Strategy Officer2.05MN/A1956
Dr. S. J. Rupert Vessey MA, BM BCh, FRCP, DPhilPres of Research & Early Devel.2.51MN/A1965
Dr. Alise Reicin M.D.Pres of Global Clinical Devel.1.37MN/A1961
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

Corporate Governance

Celgene Corporation’s ISS Governance QualityScore as of April 1, 2019 is 4. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.